Clinical Trial Update: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of everolimus and pasireotide (SOM230) in advanced or metastatic hepatocellular carcinoma has completed enrollment an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Pasireotide (pasireotide)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Advanced Adult Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-04-07